OncoMatch/Clinical Trials/NCT06503094
CD19 & CD20 Bispecific CAR T Cells for Relapsed / Refractory B Cell Hematological Tumors
Is NCT06503094 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies CD19&CD20 bispecific CAR-T cells for b-cell lymphoblastic leukemia/lymphoma.
Treatment: CD19&CD20 bispecific CAR-T cells — This study is a multi-center, open, prospective single-arm clinical study of patients with relapsed / refractory B cell hematological tumors to evaluate the safety and efficacy of CD19 \& CD20 bispecific CAR-T cells in relapsed / refractory B cell hematological tumors while collecting pharmacokinetics and pharmacodynamics indicators of CAR-T cells.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD19 overexpression (positive)
The results of FCM or immunohistochemical detection of tumor antigen (CD 19 / CD 20) were positive.
Required: CD20 overexpression (positive)
The results of FCM or immunohistochemical detection of tumor antigen (CD 19 / CD 20) were positive.
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: monoclonal antibody against CD20
Subject must have received prior adequate treatment, including at least: a monoclonal antibody against CD 20 and combination chemotherapy containing an anthracycline drug agent.
Must have received: anthracycline
combination chemotherapy containing an anthracycline drug agent
Lab requirements
Liver function
Active hepatitis (hepatitis B virus deoxyribonucleic acid [HBV-DNA 500 IU / ml and abnormal liver function] or hepatitis C antibody [HCV-Ab] positive, HCV-RNA above the lower limit of detection of the analytical method and abnormal liver function) [excluded]
Cardiac function
Appearance of one of the following cardiac criteria: atrial fibrillation; myocardial infarction in the last 12 months; prolonged QT syndrome or secondary QT extension, as judged by the investigator. Echocardiography LVSF <30% or LVEF <50%; clinically significant pericardial effusion; cardiac insufficiency NYHA III or IV (confirmed by echocardiography within 12 months of treatment).
Appearance of one of the following cardiac criteria: atrial fibrillation; myocardial infarction in the last 12 months; prolonged QT syndrome or secondary QT extension, as judged by the investigator. Echocardiography LVSF <30% or LVEF <50%; clinically significant pericardial effusion; cardiac insufficiency NYHA (New York Heart Association) III or IV (confirmed by echocardiography within 12 months of treatment). Active hepatitis (hepatitis B virus deoxyribonucleic acid [HBV-DNA 500 IU / ml and abnormal liver function] or hepatitis C antibody [HCV-Ab] positive, HCV-RNA above the lower limit of detection of the analytical method and abnormal liver function).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify